Compare Harmony Gold Mining Co. (HMY) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harmony Gold Mining Co. vs Novartis AG — how do they compare? Harmony Gold Mining Co. trades at $15.32 (market cap $9.07B), while Novartis AG trades at $153.88 (market cap $290.25B). The key difference: Novartis AG is far larger — about 32× Harmony Gold Mining Co.'s market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| HMY | NVS | |
|---|---|---|
Market Cap | $9.07B | $290.25B |
Sector | Basic Materials | Health |
52-Week High | $26.04 | $168.62 |
52-Week Low | $12.61 | $113.50 |
Enterprise Value | $9.41B | $330.27B |
Dividend Yield | 2.84% | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harmony Gold Mining (HMY) trades at $15.325, up 4.61% today, but technical indicators signal a bearish trend with key resistance at $15. The company reported strong 2024 results with revenue of $61.38B and net income of $8.59B, yet recent earnings missed expectations. Cash flow from operations improved to $15.65B in 2024, though 2025 projections show a net cash outflow. Analyst sentiment is mixed, with 70% hold ratings, reflecting caution amid gold price volatility and Fed rate hike concerns.
The outlook for HMY hinges on gold and copper price stability, with operational execution critical. Investment opportunities include a low P/E of 9.17 and a 4.06% dividend yield, but risks involve earnings misses, rising costs, and macroeconomic pressures. Investors should weigh strong profitability against sector headwinds and analyst skepticism.
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
